TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib
- 15 September 2022
- journal article
- research article
- Vol. 12 (9) , 4343-+
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death attributed to high fre-quency of metastasis and multiple drug resistance. We aim to examine the underlying molecular mechanism and to seek potential strategies to reverse primary/acquired resistance to regorafenib. Topoisomerase II alpha (TOP2A) is criti-cal for tumorigenesis and carcinogenesis. Clinically, high-TOP2A expression was correlated to shorter overall survival (OS) of patients, but its role in drug resistance of HCC remains unknown. Here, we screened the expression profiling of TOP2A in HCC and identified TOP2A as an upregulated gene involved in the resistance to regorafenib. Sustained exposure of HCC cells to regorafenib could upregulate the expression of TOP2A. Silencing TOP2A enhanced HCC cells' sensitivity to regorafenib. TOP2A inhibition by doxorubicin or epirubicin synergized with regorafenib to sup-press the growth of sorafenib-resistant HCC tumors that possessed the sorafenib-resistant features both in vitro and in vivo. Thus, targeting TOP2A may be a promising therapeutic strategy to alleviate resistance to regorafenib and thus improving the efficacy of HCC treatment.Keywords
This publication has 59 references indexed in Scilit:
- Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell CarcinomaEuropean Urology, 2014
- Expression of Topoisomerase II-α in Triple Negative Breast CancerApplied Immunohistochemistry & Molecular Morphology, 2014
- Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα ExpressionMolecular Cancer Therapeutics, 2013
- 4β-[4′-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agentsBioorganic & Medicinal Chemistry, 2013
- How does doxorubicin work?eLife, 2012
- Apoptosis in cancer: from pathogenesis to treatmentJournal of Experimental & Clinical Cancer Research, 2011
- Translational Control of TOP2A Influences Doxorubicin EfficacyMolecular and Cellular Biology, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cellsHepatology, 2010
- Functional Interaction of DNA Topoisomerase IIα With the β-Catenin and T-Cell Factor-4 ComplexGastroenterology, 2007